[Federal Register Volume 65, Number 106 (Thursday, June 1, 2000)]
[Notices]
[Page 35108]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-13733]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: ``Anti-Notch Antibodies 
and Pharmaceutical Compositions for the Therapeutic Treatment of Tumors 
Which Over Express Notch Protein''

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
404.7(a)(1)(i) that the National Institutes of Health, Department of 
Health and Human Services, is contemplating the grant of an exclusive 
world-wide license to U.S. Patent Applications 60/124,119, entitled: 
``Anti-Notch-1 Monoclonal Antibodies for Inducing Cellular 
Differentiation and Apoptosis'' and 60/102,816, entitled: ``Apoptosis 
Inducing Agents and Methods'' plus, if available, corresponding foreign 
patent applications to Viragen, Inc. having a place of business in 
Plantation, Florida. The patent rights in these inventions have been 
assigned to the United States of America.

DATES: Only written comments and/or applications for a license which 
are received by NIH on or before July 31, 2000 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
comments and other materials relating to the contemplated licenses 
should be directed to: J.R. Dixon, Ph.D., Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804. Telephone: (301) 496-7735 ext. 206; Facsimile: (301) 402-0220. A 
signed Confidentiality Agreement will be required to receive copies of 
the patent applications.

SUPPLEMENTARY INFORMATION: The technology disclosed in USPA SN: 60/
124,119 and 60/102,816 relates to a method, pharmaceutical composition, 
and antibodies to treat tumors by causing apoptosis in tumor cells that 
over express Notch protein.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    The field of use may be limited to the use of anti-Notch antibodies 
and pharmaceutical composition for the diagnosis and therapeutic 
treatment of tumors which over express Notch protein.
    Applications for a license [i.e., completed ``Application for 
License to Public Health Service Inventions] in the field of use of 
anti-Notch antibodies and pharmaceutical composition for the 
therapeutic treatment of tumors which over express Notch protein filed 
in response to this notice will be treated as objections to the grant 
of the contemplated license. Comments and objections will not be made 
available for public inspection and, to the extent permitted by law, 
will not be subject to disclosure under the Freedom of Information Act, 
5 U.S.C. 552.

    Dated: May 22, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 00-13733 Filed 5-31-00; 8:45 am]
BILLING CODE 4140-01-P